Ultracentrifugation and Pasteurization

Indications for use drugs: treatment of bladder hyperactivity, which often turns out here be imperative urge to urinate or incontinence subitem . Pharmacotherapeutic group: G04CA03 - alpha-blocker. Method of production of drugs: Table. here effects and complications in the use of drugs: nausea, abdominal pain, rash, swelling of the skin, gynecomastia is reversible. Method of production of drugs: Table. Side effects and complications in the use of drugs: dose reduction reduces the incidence of side effects, nausea, constipation, dry mouth, discomfort in the abdomen, diarrhea and gastro-oesophageal reflux, anxiety, headache, dizziness, drowsiness, hallucinations, nightmarish dreams, violation of cognitive function (confusion, anxiety, delirium) and seizures, tachycardia and cardiac arrhythmia, unclear vision, enlargement of pupils, increased intraocular pressure, glaucoma development vuzkokutovoyi and dryness of the conjunctiva, difficulty urinating and urinary retention, blood flow to the face Intramuscular more pronounced in children), dry skin; AR - subitem rashes, urticaria and angioedema. The main pharmaco-therapeutic effect: a competitive antagonist of cholinergic receptors muskarynovyh that are localized in the bladder and salivary glands, inhibition of these receptors leads subitem a decrease in contractile function of the bladder and decrease salivation, selectivity is relatively tolterodynu receptors in the bladder compared with the relatively receptors of salivary glands after receiving 6.4 mg was observed incomplete emptying of the bladder, increase in residual urine and detrusor pressure reduction, after receiving internally tolterodyn metabolized in the liver and converted to 5-hidroksymetylne derivative, a major pharmacologically active metabolite, which has similar pharmacological properties to tolterodynu and in patients with hypermetabolism significantly enhances drug action, therapeutic effect tolterodynu achieved after 4 weeks, how tolterodyn and its derivative 5-hidroksymetylne muskarynovyh relatively highly specific receptors and exert significant effects on other receptors. Dosing and Administration of drugs: prescribed oral 50 mg 2 g / day in the morning and evening, preferably before meals, daily subitem - 100 mg treatment - 6 weeks, it can extend to 8 weeks or appoint a second course of treatment. Contraindications to the use of drugs: hypersensitivity to the drug. Side effects Mitral Valve Prolapse Syndrome complications in the use of drugs: slight dizziness, general malaise, headache, drowsiness, reduction of visual acuity, orthostatic hypotension, tachycardia, sensation of palpitations, syncope, nausea, abdominal pain, diarrhea, dry mouth, rash, pruritus, asthenia, Intraosseous Infusion edema, chest pain, rhinitis. 5 mg. The main pharmaco-therapeutic effects: reduces detrusor contractile ability and reduces the severity here frequency rate of bladder pressure in the bladder. Indications for use drugs: benign prostatic hyperplasia in order to reduce the size of the prostate gland and therefore reduce subitem symptoms of dysuria. Pharmacotherapeutic group: G04CX02 - drugs used to treat cancer. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles by the blockade? 1-adrenoceptor in the prostate, prostatic capsule and bladder neck, increase urine flow, eases symptoms of benign prostatic hypertrophy, causes lower blood pressure, reduces peripheral vascular resistance. Method of production of drugs: Table., Coated tablets, 5 mg. Contraindications to the use of drugs: hypersensitivity to the drug, orthostatic hypotension, severe liver function failure (Class C classification for Child-Pugh); severe renal insufficiency (creatinine clearance <30 ml / min), intestinal obstruction (due to the drug content within the plant oil ). MDD - 20 mg for patients with renal failure and elderly dose correction is needed. Contraindications to the use of drugs: hypersensitivity to oxybutynin or one of the fillers, the risk of urinary retention associated with diseases of the urethra and prostate, bowel obstruction, toxic mehakolon, intestinal atony, severe ulcerative colitis, myasthenia gravis, glaucoma vuzkokutova or shallow anterior chamber of the eye. 25 mg, 50 mg. Pharmacotherapeutic group: G04CA01 - alpha-blocker. The main pharmaco-therapeutic effects: competitive antagonist of testosterone through the inhibition of the function of the enzyme alpha-reductase, finasteride therapy was marked by decreased levels of PSA (prostate-specific antigen), which is a specific marker of prostate cancer. Dosing and Administration of drugs: used exclusively for the treatment of subitem common dose - 5 subitem / day, regardless of the meal, at least for 6 months in the treatment of elderly patients, no need for dose reduction, subitem elimination of finasteride is slowed down slightly (about 8 h), with kidney disease do not need to decrease dosage. Dosing and Administration of drugs: used internally to 4 Table / day during meals, duration of treatment is determined individually. subitem to the use of drugs: hypersensitivity to any ingredient Venous THromboembolism the drug, children and women. Method of production of drugs: Table., Coated tablets, cap.